With major backing from New York and China, Athenex sets sights on a $100M cancer drug IPO
Johnson Lau wants to make his comeback as CEO of a public biotech company, even though the last outing 15 years ago didn’t go so well.
Lau and his crew have set their sights on a $100 million windfall for Athenex, a Buffalo-based cancer drug developer which has made a commitment to hire hundreds of staffers to win a $200 million commitment from the state to fund the construction of a new manufacturing complex.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.